US to test benefits of remdesivir with second drug

The U.S. has begun the third phase of its remdesivir study, testing the antiviral drug's effectiveness in treating COVID-19 when taken alongside beta interferon, another antiviral and anti-inflammatory drug.

During the trial, 1,000 COVID-19 patients will receive either remdesivir and a placebo or remdesivir and beta interferon.